Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results

Stock Information for Vaxart Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vaxart Inc.

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.